NRIX Nurix Therapeutics, Inc.
$26.70▲ +4.50%
Healthcare
Other
After hours
$26.92▲ +0.82%
Oct 27, 5:37 PM ET
Volume 2.56M
Avg Volume (10D) 3.27M
Key Metrics & Fundamentals
Market Cap
$2.92B
P/E Ratio
11.0
Div Yield
0.00%
52W Range
11.37 - 28.23
% vs 50 MA
6.83%
% vs 200 MA
33.15%
RSI-14
65.8
MACD Histogram
+0.3800
Beta (1Y vs SPY)
1.19
Free Cash Flow
$614.24M
Gross Rev
$673.06M
Gross Profit
$673.06M
EBITDA
$563.07M
COGS
–
Operating Exp
$113.61M
Operating Income
$559.45M
EBIT
$559.45M
Pretax Income
$563.41M
Net Income
$549.81M
EPS (Diluted)
4.73
Price & Volume History
Loading chart…
Recent News
Could You Have Seen The Run In Kymera Stock Coming?
Trefis · Oct 26, 2026 5:34 PM ET
Roche's 9M 2026 Sales Rise on Strong Drug Demand, Pipeline Advances
Zacks · Oct 22, 2026 1:35 PM ET
What Nurix Therapeutics Stock's Profit Turnaround Means For Shareholders
Simply Wall St. · Oct 22, 2026 2:19 AM ET
Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?
Zacks · Oct 19, 2026 9:08 AM ET
Big Pharma Is Pouring Billions Into a New Class of ‘Protein Degrader’ Drugs
The Wall Street Journal · Oct 15, 2026 5:30 AM ET
Nurix Therapeutics Insider Sold Shares Worth $528,528, According to a Recent SEC Filing
MT Newswires · Oct 14, 2026 4:19 PM ET
Nurix Therapeutics' Enterprise Value Remains Underappreciated, RBC Capital Markets Says
MT Newswires · Oct 13, 2026 12:23 PM ET
Cathie Wood Has Sold Nearly $18 Million of Meta in Days -- Here's What It Means
GuruFocus.com · Oct 13, 2026 11:47 AM ET
Oppenheimer Adjusts Price Target on Nurix Therapeutics to $32 From $28, Maintains Outperform Rating
MT Newswires · Oct 13, 2026 8:56 AM ET
RBC Trims Price Target on Nurix Therapeutics to $35 From $36, Keeps Outperform, Speculative Risk
MT Newswires · Oct 13, 2026 7:51 AM ET
Financial Overview - Income Statement
Quarterly
Aug 2026
See NRIX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.